Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    October 2022
  1. YIBIRIN M, Hosry J, Yepez Guevara E, Granwehr BP, et al
    High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2022;34:1098-1101.
    PubMed     Abstract available


    September 2022
  2. GARRIDO I, Liberal R, Peixoto A, Macedo G, et al
    "Long-term follow-up and prognosis of celiac hepatitis".
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00077.
    PubMed     Abstract available


    July 2022
  3. HUNYADY P, Herrmann E, Bojunga J, Friedrich-Rust M, et al
    Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury.
    Eur J Gastroenterol Hepatol. 2022;34:801-806.
    PubMed     Abstract available


  4. PARIENTE A, Rosa I, Dharancy S, Hanslik B, et al
    Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study).
    Eur J Gastroenterol Hepatol. 2022;34:791-800.
    PubMed     Abstract available


    May 2022
  5. SUN J, Yu X, Weng Z, Jin L, et al
    The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease.
    Eur J Gastroenterol Hepatol. 2022 May 5. pii: 00042737-990000000-00024.
    PubMed     Abstract available


  6. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
    Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
    Eur J Gastroenterol Hepatol. 2022;34:560-566.
    PubMed     Abstract available


    April 2022
  7. ALLGEIER J, Weber S, Todorova R, Neumann J, et al
    Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort.
    Eur J Gastroenterol Hepatol. 2022;34:457-461.
    PubMed     Abstract available


    March 2022
  8. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
    Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
    Eur J Gastroenterol Hepatol. 2022;34:308-315.
    PubMed     Abstract available


    February 2022
  9. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
    Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
    PubMed     Abstract available


  10. HUANG X, Wang H, Zhang W, Gu E, et al
    Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97084.
    PubMed     Abstract available


    December 2021
  11. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
    Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
    PubMed     Abstract available


  12. NG A
    Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  13. NG A
    Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  14. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  15. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  16. HUBBARD A, Hirode G, Chitnis A, Wong R, et al
    Prevalence of hepatitis B surface antigen and hepatitis B core antibody among adults with latent tuberculosis infection.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    September 2021
  17. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available


  18. PATACCINI G, Pedrozo W, Mathet VL, Biglione MM, et al
    Prevalence of hepatitis D virus in blood donors with different hepatitis B virus markers of infection.
    Eur J Gastroenterol Hepatol. 2021;33:1229.
    PubMed    


  19. PI B, Wang J, Tong Y, Yang Q, et al
    Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Eur J Gastroenterol Hepatol. 2021 Sep 1. pii: 00042737-900000000-97150.
    PubMed     Abstract available


    July 2021
  20. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available


  21. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available


    June 2021
  22. LIU X, Zhang J, Wei X, Duan Z, et al
    HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97185.
    PubMed     Abstract available


  23. KHAN A, Sami K, Malik A, Mujtaba Bhinder M, et al
    Clinical outcomes and healthcare utilization of acute hepatitis A virus infection with acute kidney injury in hospitalized patients.
    Eur J Gastroenterol Hepatol. 2021 Jun 17. pii: 00042737-900000000-97190.
    PubMed     Abstract available


    May 2021
  24. KOSEKLI MA
    Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97205.
    PubMed     Abstract available


  25. SHI K, Li P, Xue D, Liu Y, et al
    Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97202.
    PubMed     Abstract available


    April 2021
  26. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available


  27. EKMEN N, Can G, Can H
    Preliminary examination of the relations between disease stage, illness perceptions, coping strategies, and psychological morbidity in chronic hepatitis B and C guided by the Common-Sense Model of Illness.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97249.
    PubMed     Abstract available


  28. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available


  29. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available


    January 2021
  30. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: